Results 61 to 70 of about 20,820 (198)

Preferred antiretroviral drugs for the next decade of scale up [PDF]

, 2012
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle, Cahn, Pedro, Calmy, Alexandra, Clayden, Polly, Ford, Nathan, Goemaere, Eric, Katlama, Christine, Levin, Andrew, Lynch, Sharonann, Raguin, Gilles, Vitoria, Marco   +10 more
core   +4 more sources

Effect of Testosterone Therapy on Cytochrome P450 3A and P‐Glycoprotein Activities Using Midazolam and Digoxin as Probe Substrates Among Transgender Adults

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT Background Gender‐affirming testosterone therapy is one part of the standard of care for more than 1 million transgender adults in the United States. Testosterone therapy may influence the activities of drug‐metabolizing enzymes and transporters, but knowledge about its effect on the pharmacokinetics of other medications is limited.
Michiko Hunter, Rene Coig, Linda Risler, Kristen K. Patton, Radhika R. Narla, Dina N. Greene, Alson K. Burke, Elizabeth Micks, Mary F. Hebert, Lauren R. Cirrincione   +9 more
wiley   +1 more source

Ethical Allocation of Preexposure HIV Prophylaxis [PDF]

, 2011
Civil society-led movements transformed global AIDS action from deep skepticism about extending anti-retroviral (ARV) treatment in low and middle-income countries to an historic scaling up of treatment towards universal access.
Gostin, Lawrence O., Kim, Susan C.
core   +1 more source

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection [PDF]

, 2013
Introduction: Resistance in nucleoside/nucleotide analog (NA) therapy has always been a challenge in the management of chronic hepatitis B (CHB). Clinical studies: Initially developed for the treatment of HIV infection, early in vitro and clinical ...
Fung, J, Lai, CL, Seto, WK, Yuen, MF
core   +1 more source

Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The aim of this study was to evaluate 10‐year long‐term clinical and virological outcomes after 96 weeks of treatment with PEG ...
Cihan Yurdaydin, Julia Kahlhöfer, Florin Alexandru Caruntu, Kendal Yalcin, Selim Gürel, Ulus S. Akarca, Kathrin Sprinzl, Hans H. Bock, Jan‐Hendrik Bockmann, George V. Papatheodoridis, Uta Merle, Münevver Demir, Svenja Hardtke, Onur Keskin, Ramazan Idilman, Markus Cornberg, Heiner Wedemeyer, Anika Wranke   +17 more
wiley   +1 more source

Investigating the effect of selected antiretroviral therapies on serum testosterone and testicular microstructure of Wistar rats

Ibom Medical Journal, 2021
Background: Highly active antiretroviral therapies (HAARTs) and other antiretroviral therapies (ARTs) are widely used in the management of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) as well as repurposing for other ...
Edagha IA, Umoh VA, Peter AI, Asuquo IE, Udofot E, Archibong KE   +5 more
doaj   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults

Journal of the International Association of Providers of AIDS Care, 2019
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015 ...
Oche O. Agbaji MBBS, Isaac O. Abah B.Pharm, MPH, Augustine O. Ebonyi MBBS, MSc, Zumnan M. Gimba MBBS, Esla E. Abene MBBS, Simji S. Gomerep MBBS, Kakjing D. Falang PhD, Joseph Anejo-Okopi PhD, Patricia A. Agaba MBBS, Placid O. Ugoagwu BSc, Emmanuel I. Agaba MBBS, Godwin E. Imade PhD, Atiene S. Sagay MBBS, Prosper Okonkwo MBBS, John A. Idoko MBBS, Phyllis J. Kanki DVM, DSc   +15 more
doaj   +1 more source

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women [PDF]

, 2011
The early closure of a clinical trial assessing the effectiveness of oral antiretroviral pre-exposure prophylaxis (PrEP) in women, FEM-PrEP, is a substantial setback for HIV prevention.
Abdool Karim, Angela DM Kashuba, Dumond, Grant, Karim, Lise Werner, Quarraisha Abdool Karim, Salim S Abdool Karim   +7 more
core   +2 more sources